[{"id":"7c4709ee-03b2-4e5b-b8af-61df0f32ed05","acronym":"NCI-2018-01788","url":"https://clinicaltrials.gov/study/NCT03670966","created_at":"2021-01-18T18:00:29.277Z","updated_at":"2025-02-25T16:44:27.913Z","phase":"Phase 1/2","brief_title":"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT03670966 - NCI-2018-01788","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • Iomab-B (I-131-apamistamab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/10/2019","start_date":" 07/10/2019","primary_txt":" Primary completion: 06/28/2027","primary_completion_date":" 06/28/2027","study_txt":" Completion: 03/20/2029","study_completion_date":" 03/20/2029","last_update_posted":"2025-02-05"},{"id":"937bec61-abb0-4838-bc7e-ee7138f0f459","acronym":"MED20-165","url":"https://clinicaltrials.gov/study/NCT04512716","created_at":"2021-01-18T21:37:46.095Z","updated_at":"2024-07-02T16:35:15.633Z","phase":"Phase 1","brief_title":"Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT04512716 - MED20-165","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iomab-B (I-131-apamistamab) • apamistamab-I-131 (Iomab-ACT) • vadacabtagene leraleucel (JCAR015)"],"overall_status":"Recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 02/02/2021","start_date":" 02/02/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-08"},{"id":"99fd1b20-e5d8-4f4e-b908-4bdb8158c160","acronym":"SIERRA","url":"https://clinicaltrials.gov/study/NCT02665065","created_at":"2021-01-18T12:59:29.161Z","updated_at":"2024-07-02T16:35:42.652Z","phase":"Phase 3","brief_title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT02665065 - SIERRA","lead_sponsor":"Actinium Pharmaceuticals","biomarkers":" HLA-DRB1 • PTPRC • HLA-B • HLA-C","pipe":" | ","alterations":" PTPRC expression","tags":["HLA-DRB1 • PTPRC • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTPRC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cytarabine • doxorubicin hydrochloride • azacitidine • cyclophosphamide • Iomab-B (I-131-apamistamab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-07-19"}]